Skip to main content
Clinical Trials/NCT06151223
NCT06151223
Recruiting
Not Applicable

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Mayo Clinic1 site in 1 country5,000 target enrollmentJuly 13, 2021

Overview

Phase
Not Applicable
Intervention
Bio-specimen Collection: Blood
Conditions
Pancreatic Cancer
Sponsor
Mayo Clinic
Enrollment
5000
Locations
1
Primary Endpoint
Collection of radiology images and videos
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.

Registry
clinicaltrials.gov
Start Date
July 13, 2021
End Date
July 31, 2031
Last Updated
last month
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 year
  • Able to provide written informed consent
  • Meets criteria as a High-Risk Individual as defined by protocol

Exclusion Criteria

  • Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC)
  • History of total pancreatectomy

Arms & Interventions

Tier 1

* Participants with Peutz-Jeghers syndrome and/or carriers of a germline CDKN2A mutation and/or hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative) * Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative) * At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and/or at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and/or at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)

Intervention: Bio-specimen Collection: Blood

Tier 1

* Participants with Peutz-Jeghers syndrome and/or carriers of a germline CDKN2A mutation and/or hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative) * Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative) * At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and/or at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and/or at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)

Intervention: Bio-specimen Collection: Pancreatic Juice

Tier 2

* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative * OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \> 45 who do not meet tier 1 criteria.

Intervention: MRI

Tier 2

* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative * OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \> 45 who do not meet tier 1 criteria.

Intervention: Bio-specimen Collection: Blood

Tier 2

* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative * OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \> 45 who do not meet tier 1 criteria.

Intervention: Bio-specimen Collection: Pancreatic Juice

Outcomes

Primary Outcomes

Collection of radiology images and videos

Time Frame: Up to 10 years

Collect and archive radiology images and videos obtained during esophagogastroduodenoscopy (EDG)-endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) in high risk individuals undergoing screening and surveillance tests. An imaging dataset designed for studies of promising imaging biomarkers and developing AI-assisted algorithms can be collected within10 years.

Collection of biospecimen samples (blood and pancreatic juice)

Time Frame: Up to 10 years

Sufficient biospecimens (blood and pancreatic juice) will be collected in 10 years from participants to provide a resource for nested case-control studies of promising biomarkers for discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC)..

Study Sites (1)

Loading locations...

Similar Trials